EU mulls new Prevnar 13 indication

Share this article:

The EU is mulling an expanded indication for Pfizer's pneumococcal vaccine Prevnar 13. PM Live reports that expanding the use to include prevention of community-acquired pneumonia among the elderly could mean an additional $1 billion in sales. The drug is already approved for preventing invasive pneumococcal diseases among adults.

The US is set to consider an expanded indication in September, and the US Advisory Committee on Immunization Practices is expected to weigh in sometime this month.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions